NPS Pharmaceuticals Price Target Increased to $28.00 by Analysts at Oppenheimer (NPSP)
Investment analysts at Oppenheimer hoisted their target price on shares of NPS Pharmaceuticals (NASDAQ:NPSP) from $19.00 to $28.00 in a note issued to investors on Wednesday, ARN reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price objective suggests a potential upside of 20.43% from the stock’s previous close.
The analysts wrote, “We conducted a survey of 25 community gastroenterologists to assess their current view on Gattex and the future growth potential for the drug. Our results show that while most docs are aware of Gattex, most of their patients are not. Over the next three years our surveyed physicians plan to increase their Gattex prescriptions significantly, part of which is likely to be driven by increased patient awareness, positive feedback from initial patients, and improved reimbursements. Based on the results of this survey we are raising our price target for NPS from $19/share to $28/share and reiterate our Outperform rating.”
Shares of NPS Pharmaceuticals (NASDAQ:NPSP) traded up 2.58% on Wednesday, hitting $23.85. 460,907 shares of the company’s stock traded hands. NPS Pharmaceuticals has a one year low of $7.35 and a one year high of $24.79. The stock’s 50-day moving average is $19.03 and its 200-day moving average is $15.14. The company’s market cap is $2.419 billion.
NPS Pharmaceuticals (NASDAQ:NPSP) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.13) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.07) by $0.06. The company had revenue of $36.50 million for the quarter, compared to the consensus estimate of $31.62 million. During the same quarter last year, the company posted $0.08 earnings per share. NPS Pharmaceuticals’s revenue was down 31.8% compared to the same quarter last year. On average, analysts predict that NPS Pharmaceuticals will post $-0.21 earnings per share for the current fiscal year.
NPSP has been the subject of a number of other recent research reports. Analysts at BMO Capital Markets raised their price target on shares of NPS Pharmaceuticals from $14.00 to $19.00 in a research note to investors on Tuesday, August 13th. They now have a “market perform” rating on the stock. Separately, analysts at Zacks downgraded shares of NPS Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Monday, August 12th. They now have a $23.30 price target on the stock. Finally, analysts at Wedbush raised their price target on shares of NPS Pharmaceuticals from $22.00 to $29.00 in a research note to investors on Friday, August 9th. They now have an “outperform” rating on the stock.
Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $23.63.
NPS Pharmaceuticals, Inc (NASDAQ:NPSP) is a clinical-stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.